SK286631B6 - Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy - Google Patents

Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy Download PDF

Info

Publication number
SK286631B6
SK286631B6 SK1026-2000A SK10262000A SK286631B6 SK 286631 B6 SK286631 B6 SK 286631B6 SK 10262000 A SK10262000 A SK 10262000A SK 286631 B6 SK286631 B6 SK 286631B6
Authority
SK
Slovakia
Prior art keywords
aqueous solution
cefditoren pivoxil
additive
particles
precipitate
Prior art date
Application number
SK1026-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK10262000A3 (sk
Inventor
Masahiro Onodera
Masamichi Sukegawa
Kiyoshi Yasui
Tatsuo Watanabe
Toyomi Sato
Yasushi Murai
Katsuharu Iinuma
Original Assignee
Meiji Seika Kaisha Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha Ltd. filed Critical Meiji Seika Kaisha Ltd.
Publication of SK10262000A3 publication Critical patent/SK10262000A3/sk
Publication of SK286631B6 publication Critical patent/SK286631B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK1026-2000A 1998-01-07 1999-01-07 Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy SK286631B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP192098 1998-01-07
PCT/JP1999/000020 WO1999034832A1 (fr) 1998-01-07 1999-01-07 Compositions de cephalosporine amorphes, stables du point de vue cristallographique et procede de preparation de ces compositions

Publications (2)

Publication Number Publication Date
SK10262000A3 SK10262000A3 (sk) 2001-01-18
SK286631B6 true SK286631B6 (sk) 2009-02-05

Family

ID=11515039

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1026-2000A SK286631B6 (sk) 1998-01-07 1999-01-07 Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy

Country Status (23)

Country Link
US (2) US6342493B1 (hu)
EP (1) EP1051978B1 (hu)
JP (1) JP3413406B2 (hu)
KR (1) KR100435315B1 (hu)
CN (1) CN1151845C (hu)
AU (1) AU736555B2 (hu)
BR (1) BRPI9907084B8 (hu)
CA (1) CA2316841C (hu)
CZ (1) CZ302082B6 (hu)
EA (1) EA002881B1 (hu)
ES (1) ES2393972T3 (hu)
HK (1) HK1035148A1 (hu)
HU (1) HU230295B1 (hu)
ID (1) ID25469A (hu)
IL (2) IL137004A0 (hu)
NZ (1) NZ505871A (hu)
PL (1) PL194097B1 (hu)
PT (1) PT1051978E (hu)
SK (1) SK286631B6 (hu)
TR (1) TR200001903T2 (hu)
TW (1) TW587946B (hu)
UA (1) UA70311C2 (hu)
WO (1) WO1999034832A1 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100435315B1 (ko) * 1998-01-07 2004-06-10 메이지 세이카 가부시키가이샤 결정학적으로 안정된 비정질 세파로스포린 조성물과 그제조 방법
AU773218B2 (en) 1999-10-08 2004-05-20 Debiopharm International Sa Fab I inhibitors
DE60230934D1 (de) 2001-04-06 2009-03-05 Affinium Pharm Inc Fab-i-inhibitoren
CN1537005A (zh) * 2001-04-26 2004-10-13 �����Ƹ���ʽ���� 无定形头孢托仑匹伏克西路组合物及其制备方法
MXPA05003357A (es) * 2002-10-02 2005-06-22 Meiji Seika Kaisha Composicion medicinal antibacteriana de capacidad de absorcion oral mejorada.
JP4859460B2 (ja) 2002-12-06 2012-01-25 アフィニウム ファーマシューティカルズ, インク. ヘテロ環化合物、その製造方法および治療におけるその使用
CA2519429C (en) * 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
WO2004113451A1 (ja) * 2003-06-20 2004-12-29 Meiji Seika Kaisha, Ltd. 難溶性物質と水溶性高分子との共沈物およびその製造方法
US20070053973A1 (en) * 2003-10-08 2007-03-08 Shigeru Chikase Amorphous antibiotic composition comprising cefditoren pivoxil
CN1902207A (zh) * 2003-11-07 2007-01-24 兰贝克赛实验室有限公司 高纯度3-(2-取代乙烯基)头孢菌素的制备方法
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
WO2005082330A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
WO2007053131A2 (en) 2004-06-04 2007-05-10 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as antibiotic agents
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
CA2658506C (en) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab 1 inhibitors
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
CN101560216B (zh) * 2009-05-27 2011-06-15 上海交通大学 头孢妥仑酯的制备方法
WO2012010938A2 (en) * 2010-07-23 2012-01-26 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
MY161429A (en) 2010-09-30 2017-04-14 Toyama Chemical Co Ltd Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
SG188662A1 (en) 2010-09-30 2013-05-31 Toyama Chemical Co Ltd Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
WO2013190384A1 (en) 2012-06-19 2013-12-27 Affinium Pharmaceuticals, Inc. Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
EP3039011A1 (en) * 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
MX2018010254A (es) 2016-02-26 2018-12-19 Debiopharm Int Sa Medicamento para el tratamiento de infecciones de pie diabetico.
CN109053768A (zh) * 2018-08-07 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种无定型头孢妥仑酯的制备方法
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN112190539B (zh) * 2020-11-10 2021-11-02 深圳立健药业有限公司 一种头孢妥仑匹酯组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH05306227A (ja) * 1992-04-27 1993-11-19 Lion Corp 徐放性口腔内疾患治療剤
JP2576927B2 (ja) * 1992-05-15 1997-01-29 ファイザー製薬株式会社 細粒核
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
AR004014A1 (es) * 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
HU224196B1 (hu) * 1996-09-20 2005-06-28 Meiji Seika Kaisha Ltd. Cefditoren-pivoxil kristályos formája, és eljárás annak előállítására
KR100435315B1 (ko) * 1998-01-07 2004-06-10 메이지 세이카 가부시키가이샤 결정학적으로 안정된 비정질 세파로스포린 조성물과 그제조 방법

Also Published As

Publication number Publication date
US6342493B1 (en) 2002-01-29
ES2393972T8 (es) 2013-02-25
CA2316841C (en) 2007-11-20
HU230295B1 (hu) 2015-12-28
UA70311C2 (uk) 2004-10-15
CA2316841A1 (en) 1999-07-15
WO1999034832A1 (fr) 1999-07-15
CZ302082B6 (cs) 2010-09-29
ES2393972T3 (es) 2013-01-03
IL137004A (en) 2008-11-03
CZ20002542A3 (cs) 2000-12-13
NZ505871A (en) 2002-10-25
IL137004A0 (en) 2001-06-14
BRPI9907084B1 (pt) 2017-04-25
JP3413406B2 (ja) 2003-06-03
EA200000742A1 (ru) 2001-02-26
KR100435315B1 (ko) 2004-06-10
CN1151845C (zh) 2004-06-02
PL341589A1 (en) 2001-04-23
TR200001903T2 (tr) 2000-11-21
HUP0101272A2 (hu) 2001-12-28
WO1999034832A8 (fr) 1999-10-28
BRPI9907084B8 (pt) 2021-05-25
SK10262000A3 (sk) 2001-01-18
HUP0101272A3 (en) 2002-07-29
HK1035148A1 (en) 2001-11-16
CN1290177A (zh) 2001-04-04
BR9907084A (pt) 2000-10-17
EP1051978A4 (en) 2007-05-02
PT1051978E (pt) 2012-11-20
PL194097B1 (pl) 2007-04-30
US20020037322A1 (en) 2002-03-28
EP1051978A1 (en) 2000-11-15
EA002881B1 (ru) 2002-10-31
EP1051978B1 (en) 2012-08-22
AU736555B2 (en) 2001-08-02
KR20010033961A (ko) 2001-04-25
US6486149B2 (en) 2002-11-26
AU1784599A (en) 1999-07-26
TW587946B (en) 2004-05-21
ID25469A (id) 2000-10-05

Similar Documents

Publication Publication Date Title
SK286631B6 (sk) Žltá prášková kompozícia na orálne podávanie a spôsob jej prípravy
CA2552463C (en) New compositions containing quinoline compounds
KR101880255B1 (ko) 리팍시민 및 아미노산을 포함하는 약학적 조성물, 이의 제조방법 및 용도
SK283674B6 (sk) Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
SK284973B6 (sk) Kryštalická forma Cefditoren pivoxylu a spôsob jej výroby
IL182647A (en) Oral preparation with bioavailability
JP2005504785A (ja) 結晶性クリンダマイシン遊離塩基
JP2716966B2 (ja) 結晶性クラバラン酸カリウム及びその医薬組成物
MXPA00006722A (en) Crystallographically stable amorphous cephalosporin compositions and process for producing the same
EP0535269A1 (en) Pharmaceutical compositions containing thiazolidinedione derivatives
CA2052637A1 (en) Pharmaceutical preparation having an improved absorption property

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: MEIJI SEIKA PHARMA CO., LTD, CHUO-KU, TOKYO, JP

Effective date: 20120309

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20150107